Press Release Details

Cerus Corporation Invites You to Join a Webcast of its Fourth Quarter and Year End Financial Results Conference Call

January, 26 2004

CONCORD, Calif.--(BUSINESS WIRE)--Jan. 26, 2004

In conjunction with Cerus Corporation's (Nasdaq:CERS) report of fourth quarter and year end financial results, you are invited to listen to its conference call that will be broadcast live over the Internet on January 29, 2004 at 4:30 p.m. ET with Stephen Isaacs, President and Chief Executive Officer, Laurence Corash, M.D., Chief Medical Officer and Gregory Schafer, Chief Financial Officer.

What: Cerus Corporation fourth quarter and year end financial results with an update on progress and future outlook 
When: Thursday, January 29, 2004 at 4:30 p.m. ET
Where: How: Live over the internet -- Simply log on to the web at the address above Contact: Alexandra Santos / Cerus Corporation, 925-288-6156

The conference call is protected by copyright. It cannot be recorded or rebroadcast without Cerus' permission.

Cerus Corporation is developing medical systems and therapeutics to provide safer and more effective options to patients. The company is developing products based on its proprietary Helinx(R) technology for controlling biological replication. Cerus' most advanced programs are focused on systems to enhance the safety of the world's blood supply. The INTERCEPT Blood System, which is being developed in collaboration with subsidiaries of Baxter International Inc., is based on the company's Helinx technology. The INTERCEPT Blood System is designed to inactivate viruses, bacteria, other pathogens and white blood cells. The Concord, California-based company also is pursuing therapeutic applications of Helinx technology to treat and prevent serious diseases.

Helinx is a trademark of Cerus Corporation

INTERCEPT and INTERCEPT Blood are trademarks of Baxter International, Inc.

If you are unable to participate during the live webcast, the call will be temporarily archived on the Website

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600